

RECEIVED

MAR 08 2002

TECH CENTER 1600/2900

RECEIVED  
MARCH 08, 2002  
U.S. PATENT AND TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Duggan *et al.*

Appl. No. 09/529,130

§ 371 Date: June 22, 2000

For: **Conjugates as Galactose-Binding  
Lectins and Clostridial  
Neurotoxins as Analgesics**

Confirmation No.

Art Unit: 1653

Examiner: Kam, C.

Atty. Docket: 1581.0580000/RWE

02 MAR - 6 P.M. 3:9

**Second Supplemental Information Disclosure Statement**

Hand-Carry To Examiner Kam

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 is a document that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed on December 14, 2001, in connection with the above-captioned application. A copy of the cited document is also provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application.

The U.S. Patent and Trademark Office is hereby authorized to charge our Deposit Account No. 19-0036 for the fee in the amount of \$180.00 (37 C.F.R. § 1.17(p)). The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

*Bruce E. Chalker*

Bruce E. Chalker  
Attorney for Applicants  
Registration No. 47,480

Date: March 6, 2002

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600  
P:\USERS\DENISEB\1581\058supids